Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate

被引：1
|
作者：
Jacopo Giuliani [1 ]
Andrea Bonetti [1 ]
机构：
[1] Department of Oncology,Mater Salutis Hospital-ASL 21 della Regione Veneto,Legnago (VR),Italy
来源：
Chinese Journal of Cancer Research | 2013年 / 25卷 / 05期
关键词：
GIST; Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate;
D O I：
暂无
中图分类号：
R735 [消化系肿瘤];
学科分类号：
100214 ;
摘要：
Gastrointestinal stromal tumor(GIST)is the most common mesenchymal malignancy of the gastrointestinal tract.GISTs may coexist with different types of cancer,either synchronous or metachronous(1).Most GISTs develop in a sporadic fashion,but familial occurrence,such as neurofibromatosis and Carney-triad,has also been reported(2).The overall frequency of second tumors in different series varied from
引用
收藏
页码：486 / 487
页数：2
相关论文
共 50 条
  • [21] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Sith Phongkitkarun
    Cholada Phaisanphrukkun
    Janjira Jatchavala
    Ekaphop Sirachainan
    World Journal of Gastroenterology, 2008, (06) : 892 - 898
  • [22] Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty
    Yildiz, Ibrahim
    Mandel, Nil M.
    Demir, Gokhan
    Ozguroglu, Mustafa
    Toptas, Tayfur
    Buyukunal, Evin
    Serdengecti, Suheyla
    ANNALS OF ONCOLOGY, 2006, 17 : 164 - 164
  • [23] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Phongkitkarun, Sith
    Phaisanphrukkun, Cholada
    Jatchavala, Janjira
    Sirachainan, Ekaphop
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (06) : 892 - 898
  • [24] Treatment of localized anorectal gastrointestinal stromal tumors with preoperative imatinib mesylate therapy
    Wang, W.
    Luo, S.
    Chen, W.
    Kang, L.
    Deng, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S412 - S412
  • [25] Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
    Bauer, S
    Hagen, V
    Pielken, HJ
    Bojko, P
    Seeber, S
    Schütte, J
    ANTI-CANCER DRUGS, 2002, 13 (08) : 847 - 849
  • [26] Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
    Ksienski, Doran
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 365 - 379
  • [27] Survival benefit of imatinib mesylate on patients with advanced gastrointestinal stromal tumors (GIST)
    Lin, M. T.
    Hu, T. H.
    Lin, J. W.
    Wang, C. C.
    Rau, K. M.
    Changchien, C. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A44 - A44
  • [28] Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate
    Goh, B. K. P.
    Chow, P. K. H.
    Chuah, K. L.
    Yap, W. M.
    Wong, W. K.
    EJSO, 2006, 32 (09): : 961 - 963
  • [29] Immediate action of imatinib mesylate on calcium signaling in gastrointestinal stromal tumors (GIST)
    Berglund, E.
    Lu, M.
    Akcakaya, P.
    Zedenius, J.
    Nilsson, I.
    Ahlen, J.
    Lui, W.
    Larsson, C.
    Branstrom, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Cortazar, Patricia
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (03): : 300 - 307
12345